UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 256

Sortiert nach

Clonal relationship in multisited mucosa‐associated lymphoid tissue lymphomas: a single‐centre experience

British journal of haematology, 2021-03, Vol.192 (6), p.1020-1025

2021

Link zum Volltext

Verfügbarkeit prüfen

Are Biosimilars the Future of Oncology and Haematology?

Drugs (New York, N.Y.), 2019-10, Vol.79 (15), p.1609-1624

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of offline extracorporeal photopheresis in cutaneous T-cell lymphomas: A retrospective study

Photodermatology, photoimmunology & photomedicine, 2023-11, Vol.39 (6), p.667-669

2023

Link zum Volltext

Verfügbarkeit prüfen

Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication

Clinical cancer research, 2008-01, Vol.14 (1), p.155-161

2008

Link zum Volltext

Verfügbarkeit prüfen

Lenalidomide in combination with R‐ESHAP in patients with relapsed or refractory diffuse large B‐cell lymphoma: a phase 1b study from GELTAMO group

British journal of haematology, 2016-04, Vol.173 (2), p.245-252

2016

Link zum Volltext

Verfügbarkeit prüfen

In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma

Haematologica (Roma), 2018-11, Vol.103 (11), p.e537-e540

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinico‐biological features, treatment and survival of 457 patients with histological Grades 3A and 1–2 follicular lymphoma mostly treated with immunochemotherapy

British journal of haematology, 2016-02, Vol.172 (3), p.470-473

2016

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus‐associated diffuse large B‐cell lymphoma: results of a phase II trial

British journal of haematology, 2008-02, Vol.140 (4), p.411-419

2008

Link zum Volltext

Verfügbarkeit prüfen

Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome

Hematological oncology, 2017-12, Vol.35 (4), p.520-527

2017

Link zum Volltext

Verfügbarkeit prüfen

CD 30‐positive transformed follicular lymphoma: two case reports and literature review

Histopathology, 2015-12, Vol.67 (6), p.918-922

2015

Link zum Volltext

Verfügbarkeit prüfen

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

The lancet oncology, 2020-07, Vol.21 (7), p.978-988

2020

Link zum Volltext

Verfügbarkeit prüfen

Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study

Haematologica (Roma), 2022-07, Vol.107 (7), p.1633-1642

2022

Link zum Volltext

Verfügbarkeit prüfen

Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era

Frontiers in immunology, 2022-07, Vol.13, p.909008-909008

González Barca, Eva

2022

Link zum Volltext

Verfügbarkeit prüfen

Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP

British journal of haematology, 2012-06, Vol.157 (5), p.637-639

2012

Link zum Volltext

Verfügbarkeit prüfen

Multiplex ligation‐dependent probe amplification for detection of genomic alterations in chronic lymphocytic leukaemia

British journal of haematology, 2008-09, Vol.142 (5), p.793-801

2008

Link zum Volltext

Verfügbarkeit prüfen

Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy

Oncotarget, 2016-03, Vol.7 (9), p.10174-10181

2016

Link zum Volltext

Verfügbarkeit prüfen

Expert Consensus on the Characteristics of Patients with Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study

Advances in therapy, 2023-03, Vol.40 (3), p.1267-1281

2023

Link zum Volltext

Verfügbarkeit prüfen

Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies

International journal of hematology, 2023-03, Vol.117 (3), p.388-397

2023

Link zum Volltext

Verfügbarkeit prüfen

Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients

Annals of hematology, 2021-04, Vol.100 (4), p.1023-1029

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 256

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(245)
Mit Volltextzugriff
(241)

Publikationsform

Artikel
(255)
Berichte
(1)

Sprache

Englisch
(253)
Japanisch
(13)
Spanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(112)
Life Sciences & Biomedicine
(110)
Humans
(92)
Hematology
(70)
Male
(70)
Female
(68)
Aged
(61)
Middle Aged
(61)
Adult
(55)
Oncology
(40)
Prognosis
(31)
Lymphoma
(29)
Aged, 80 And Over
(28)
Biological And Medical Sciences
(27)
Medical Sciences
(27)
Treatment Outcome
(25)
Hematologic And Hematopoietic Diseases
(24)
Lymphoma, Large B-Cell, Diffuse - Drug Therapy
(24)
Rituximab
(24)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(23)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(90)
Haematologica
(32)
Journal Of Clinical Oncology
(12)
British Journal Of Haematology
(10)
Clinical Lymphoma, Myeloma And Leukemia
(10)
Medicina Clínica
(5)
Annals Of Hematology
(4)
Leukemia & Lymphoma
(4)
Oncotarget
(4)
Cancer Research
(3)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death‐ligand 1 (PD‐L1) axis in post‐transplant lymphoproliferative disorders: association with Epstein–Barr virus, PD‐L1 copy number alterations, and outcome

Clonal relationship in multisited mucosa‐associated lymphoid tissue lymphomas: a single‐centre experience

Are Biosimilars the Future of Oncology and Haematology?

Efficacy and safety of offline extracorporeal photopheresis in cutaneous T-cell lymphomas: A retrospective study

Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication

Lenalidomide in combination with R‐ESHAP in patients with relapsed or refractory diffuse large B‐cell lymphoma: a phase 1b study from GELTAMO group

Clinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution

In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma

Clinico‐biological features, treatment and survival of 457 patients with histological Grades 3A and 1–2 follicular lymphoma mostly treated with immunochemotherapy

Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus‐associated diffuse large B‐cell lymphoma: results of a phase II trial

Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome

CD 30‐positive transformed follicular lymphoma: two case reports and literature review

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

Impact of prior rituximab on outcomes of autologous stem‐cell transplantation in patients with relapsed or refractory aggressive B‐cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study

Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era

Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era

Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP

Multiplex ligation‐dependent probe amplification for detection of genomic alterations in chronic lymphocytic leukaemia

Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial

Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy

Expert Consensus on the Characteristics of Patients with Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study

Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies

Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients

Suchergebnisse filtern